N Engl J Med November 2016 PMID 27633186

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren, Vincent Woo, Oluf Hansen, Anders G Holst, Jonas Pettersson, Tina Vilsbøll

Full text PDF Download social card

Mentions

444

Peak: 77 in Sep 2019

across 7 sources since Jun 2019

Extended reach

3,063,170

potential audience

Total likes

3,351

Video views

110,090

Mentions per month

Jun 2019 – Oct 2025

Where it's discussed

X / Twitter239 posts
News141 articles
Facebook29 posts
Blogs21 articles
YouTube10 videos
Bluesky2 posts
Reddit2 posts

AI synopsis

What people are saying

Discussions consistently praise the robust evidence from trials like SUSTAIN-6 and Pioneer 6, exemplified by statements such as 'semaglutide reduces CV events by 20%' and 'shows real positive benefits.' The use of technical terms and references to specific studies demonstrates deep engagement and underscores the high impact of the findings on medical practice.

AgreementStrong agreement

Most discussions highlight the positive cardiovascular outcomes associated with semaglutide, showing strong support for its benefits.

InterestHigh interest

The discussions demonstrate high interest through mention of detailed study results, side effects, and potential implications for treatment.

EngagementHigh engagement

Many posters reference specific trials, statistics, and mechanisms, indicating deep engagement with the research.

ImpactHigh impact

The overall tone emphasizes semaglutide’s significant potential to influence treatment guidelines and improve patient outcomes.

Abstract in brief

The study assessed the cardiovascular safety of semaglutide, a diabetes treatment, in type 2 diabetes patients over a 104-week period.
Among the 3297 participants, semaglutide users had a lower incidence of cardiovascular events compared to the placebo group, indicating potential cardiovascular benefits.
However, while semaglutide showed lower rates of kidney issues, it was associated with higher rates of retinopathy complications, highlighting a need for careful monitoring.

Read the full abstract

All mentions

Understanding GLP-1 Medications for Type 2 Diabetes

Ever wonder about medications like Trulicity, Ozempic, or Victoza? This video discusses the role of GLP-1 in managing blood glucose levels, how these medications function, their benefits, and potential side effects…

Sugar High · Apr 30, 2020 93,306 views

Ozempic causes weight loss. Does it cause hair loss?

Haircafe · Jun 1, 2023 8,126 views

Impact of Ozempic, Wegovy, and Mounjaro on Body Composition

This video analyzes the impact of Ozempic, Wegovy, and Mounjaro on body composition. These GLP-1 receptor agonists have shown impressive efficacy in weight loss and altering body composition in individuals with type 2…

FalaLu! · Sep 1, 2025 6,561 views

Quantos quilos se perde com o Ozempic?

Sávio Veríssimo · Sep 7, 2025 830 views

Current Advances in Atrial Fibrillation Treatment and Endurance Athlete Cardiac Risks

This week in cardiology discusses the VENTOUX study on endurance athletes and arrhythmias, the ongoing debate between rate and rhythm control in atrial fibrillation, and the role of GLP1 drugs. The importance of…

Medscape · Jul 25, 2025 536 views

Impact of Ozempic on Eye Health Explained

Can Ozempic affect eye health? In this video, Dr. Abdul Rasheed discusses potential ocular effects associated with Ozempic, including risks of blurry vision and nonarteritic anterior ischemic optic neuropathy (NAION)…

Dr Abdul Rasheed · Sep 25, 2025 461 views

Impact of Canagliflozin on Cardiovascular and Kidney Health in Type 2 Diabetes

Huge improvements in treatments for type 2 diabetes are outlined in recent diabetes guidelines. This video discusses the effectiveness of canagliflozin in significantly reducing major cardiovascular events and…

Medscape · Feb 25, 2025 197 views

Effectiveness of DOACs in Atrial Fibrillation Management

This week’s podcast reviews significant trials including NOAH-AFNET 6 and ARTESiA that highlight the role of direct oral anticoagulants (DOACs) in preventing ischemic stroke among patients with device-detected atrial…

Medscape · Mar 27, 2024 39 views

Ozempic and Semaglutide: Effects, Risks, and Future of Weight Loss

In this video, I break down what Ozempic semaglutide really does and its impact on health, including antiaging and fat-burning effects. We explore side effects like pancreatitis and retinopathy, plus future treatments…

Divya Datta · Aug 14, 2025 23 views

Semaglutide's Cardiovascular Safety and Effects in Type 2 Diabetes

This week in cardiology, we discuss coronary CTA, semaglutide for type 2 diabetes, and upcoming cardiology events. Semaglutide showed cardiovascular benefits in a recent study, but requires monitoring for retinopathy…

Medscape · Mar 27, 2024 14 views

Bookdasa

@Totoro19514032 · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 30, 2025 · 42 shares · 12 followers View post →

Ahmed Al-Za'abi

@AhZabi · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 27, 2025 · 42 shares · 706 followers View post →

@jjogodsz · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 24, 2025 · 42 shares · 26 followers View post →

Sovichia@789

@Sovichia1993 · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 24, 2025 · 42 shares · 19 followers View post →

Syed Shahrul Naz

@drshahrul80 · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 24, 2025 · 42 shares · 6,935 followers View post →

imran robleh

@imran_rob · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 24, 2025 · 42 shares · 32 followers View post →

Gary Deed

@garydeed · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 24, 2025 · 42 shares · 115 followers View post →

jorge gamboa

@jorgega62811906 · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 24, 2025 · 42 shares · 65 followers View post →

MetaboliccareToday.com

@MetabolicCare · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 24, 2025 · 42 shares · 25 followers View post →

Victor De La Espriella Badel

@vimadelaeb · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 24, 2025 · 42 shares · 446 followers View post →

ResearchPulse

@ResearchPulse1 · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 24, 2025 · 42 shares · 1,928 followers View post →

Sharona Azriel

@SharonaAzriel · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 24, 2025 · 42 shares · 1,417 followers View post →

Wimen

@1a31551c566e43d · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 24, 2025 · 42 shares · 672 followers View post →

abhimanyu singh

@SardarAbhimanyu · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 24, 2025 · 42 shares · 11 followers View post →

Frankie

@pacovelascor · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 24, 2025 · 42 shares · 168 followers View post →

Sayantan Mukherjee

@hopelessweirdo · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 24, 2025 · 42 shares · 509 followers View post →

Abdulmohsen bakhsh د .عبدالمحسن بخش

@amohsenbakhsh · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 24, 2025 · 42 shares · 2,036 followers View post →

Yanamandra Sastri

@Yanamandra70982 · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 24, 2025 · 42 shares · 99 followers View post →

moath saleh

@moathsaleh · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 24, 2025 · 42 shares · 129 followers View post →

JOON T

@TubuloToxic · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 24, 2025 · 42 shares · 1,052 followers View post →

Jamie Wang

@jamiewang1228 · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 23, 2025 · 42 shares · 8 followers View post →

araceli miranda

@amiraveg · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 23, 2025 · 42 shares · 17 followers View post →

Niranjan Ganesh

@Drniran · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 23, 2025 · 42 shares · 185 followers View post →

Carolina Glz Fuentes

@karolas_smile · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 23, 2025 · 42 shares · 299 followers View post →

Abhishek

@aksrulz13 · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 23, 2025 · 42 shares · 631 followers View post →

Jorge Luis Rodríguez .

@JL____Rodriguez · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 23, 2025 · 42 shares · 1,354 followers View post →

MaFer Zavala

@Mafer_ZavalaM · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 23, 2025 · 42 shares · 958 followers View post →

Chih-Yao Hsu

@reclast · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 23, 2025 · 42 shares · 17 followers View post →

Roberto Gutiérrez

@DrRobertoGuti · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 23, 2025 · 42 shares · 784 followers View post →

Katty Rivera

@KattyRiveraG · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 23, 2025 · 42 shares · 203 followers View post →

Dr Jorge Ferradas Solar

@JorgeFerradasSo · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 23, 2025 · 42 shares · 1,278 followers View post →

Serigne_Fall

@fallserigne34 · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 23, 2025 · 42 shares · 2,432 followers View post →

Joyce Bwombengi

@kemuntoMD · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 23, 2025 · 42 shares · 1,084 followers View post →

Kidneyman

@Kidneyman5 · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 23, 2025 · 42 shares · 746 followers View post →

Layla Omar

@hlaylaomar · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 23, 2025 · 42 shares · 13 followers View post →

Gabriel D.C.

@GabDavC · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 23, 2025 · 42 shares · 229 followers View post →

木下卓哉

@tSMAJ2uzxBX1hoH · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 23, 2025 · 42 shares · 13 followers View post →

Joel M. Topf, MD FACP

@kidney_boy · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 23, 2025 · 42 shares · 63,684 followers View post →

Ye M. Tun, MD FACP

@DrYeMyintTun · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 23, 2025 · 42 shares · 80 followers View post →

Anjana Gopal, MBBS, MD, DM Nephrology, FASN

@AnjanaGopal9 · X

RT @edgarvlermamd: Effects of Once-Weekly

Oct 23, 2025 · 42 shares · 319 followers View post →

Edgar V. Lerma

@edgarvlermamd · X

Effects of Once-Weekly

Oct 23, 2025 · 113 likes · 42 shares · 33,855 followers View post →

Edgar V. Lerma

@edgarvlermamd.bsky.social · Bluesky

Effects of Once-Weekly Semaglutide #Nephpearls #Cardiorenal #NephSky

Oct 23, 2025 · 2 likes View post →

Edgar V. Lerma

@edgarvlermamd · X

Effects of Once-Weekly Semaglutide #Nephpearls #Cardiorenal #VisualAbstract by @AnjanaGopal9 @kidney_boy @brian_rifkin FLOW

Oct 23, 2025 · 1 like · 33,855 followers View post →

Phòng Khám MedFit

@PhongKhamMedFit · X

Marso SP, Bain SC, et al. “Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes“. N Engl J Med. 2016;375(19):1834-1844. - https://t.co/dygefqG1rI

Sep 8, 2025 · 1 followers View post →

David Ramírez Saco

@DRami15 · X

RETINOPATÍA DIABÉTICA (1/2) ❌ - La noticia la menciona como complicación, pero el prospecto habla de EMPEORAMIENTO si RD previa + insulina - Hallazgo en ensayo de no-inferioridad de resultados

Aug 21, 2025 · 371 followers View post →

Apurva Patel MD, FACC, FSCAI, RPVI

@patelapurva · X

@tehseenp Yes there are side effects and needs to be monitored closely. https://t.co/n1I3JXUtWs https://t.co/r508EbK1xT https://t.co/ickuubZa43

Jun 30, 2025 · 2 likes · 1,730 followers View post →

おだQ

@OdaQ_DM · X

PIONEER 6 Investigators. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019 Aug 29;381(9):841-851. doi: 10.1056/NEJMoa1901118. Epub 2019 Jun 11. PMID: 31185157. https://t.co/DcznGmn23E

May 8, 2025 · 3 likes · 15,213 followers View post →

NEJM Journal Watch

@JWatch · X

NEJM Group’s Dr. Lauren Westafer talks with Dr. Darren McGuire about his group’s trial on oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes who have increased cardiovascular risk. https://t.co/c5nEtE3bfG #ACC25 @LWestafer https://t.co/GsIavbfNYG

Mar 31, 2025 · 4 likes · 62,165 followers View post →

Jikkyleaks

@Jikkyleaks · X

@MaelstromCap @kevinnbass "Rates of retinopathy complications (vitreous hemorrhage, blindness, or conditions requiring treatment with an intravitreal agent or photocoagulation) were significantly higher (hazard ratio, 1.76)... " What a great drug. You read your study yeah? https://t.co/bjviNF0SiT

Dec 5, 2024 · 2 likes · 111,403 followers View post →

@_grapejulce · X

@jsjr0313 @mqyxf @memeticsisyphus semaglutide* is a GLP1 analogue, “semaglutides” are not a thing. It has been proven by clinical studies to improve cardiovascular outcomes. Not saying you shouldn’t exercise if you use it of course. But you’re not right. https://t.co/ehIOfGujxv

Dec 1, 2024 · 72 followers View post →

Dogs&Viruses

@Craigster771 · X

@UrgentKarr @jackmurphylive @FitFounder How about you read the cardiovascular outcomes studies in actual humans (non-diabetics and diabetics)? https://t.co/2QfrIf22at https://t.co/34DfC0vd8h

Nov 21, 2024 · 585 followers View post →

Dogs&Viruses

@Craigster771 · X

@FitFounder Link to actual human studies: In diabetics: https://t.co/34DfC0vd8h In non-diabetics: https://t.co/2QfrIf22at

Nov 21, 2024 · 1 like · 585 followers View post →

shaffy

@shaffy8585 · X

RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…

Nov 14, 2024 · 100 shares · 136 followers View post →

VeeJayDont

@VeeJayDo2 · X

RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…

Sep 26, 2024 · 100 shares · 1,333 followers View post →

Logos2021 Centrist, XX, Pro-Free Speech

@LogosMMXX · X

@fivehundredpou1 @MdBreathe Lots that needs to change. Concerned with emphasis on pharmacological solutions only. Need longer study of GLP-1s. The reductions (.3/100 for stroke, for ex) don't justify the massive push. Cardiovascular: https://t.co/8tk1ghNpxa Stroke: https://t.co/jkCXDO6v6u https://t.co/lUOh5XMfCf

Sep 1, 2024 · 721 followers View post →

Roots Community Health

@RootsEmpowers · X

Links Included in Briefing: Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes: https://t.co/rqX4giyteM Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: https://t.co/6mmrAYKPp7

Aug 6, 2024 · 1,681 followers View post →

REC Publications

@RevEspCardiol · X

Once weekly semaglutide and cardiovascular outcomes in patients with type 2 diabetes and heart failure with reduced left ventricular ejection fraction #REC https://t.co/nTQB1Hg3c2

Jul 22, 2024 · 22,875 followers View post →

こたつDr

@drkotatsu · X

https://t.co/iKUZXlq85n SUSTAIN6 での解析でも腎症の新規発症率、悪化率はセマグルチド群で有意に低いのに、網膜症に関連した合併症の発生率は、セマグルチド群で有意に多く認めらた（3.0％ vs. 1.8%, ハザード比:1.76, 95％CI : 1.11～2.78、P＝0.02）これに関しては別試験で検証中とは思われる https://t.co/rTkczzXcPU

Jul 5, 2024 · 3 likes · 3,592 followers View post →

Kariova

@pKariova · X

RT @joaumdoistres: Como sempre, os leigos falam do que não entendem e comparam ozempic com anabolizantes. Semaglutida reduz em 20% o risco…

Apr 20, 2024 · 1 share · 397 followers View post →

degustador de microplásticos

@joaumdoistres · X

Apr 20, 2024 · 37 likes · 1 share · 3,139 followers View post →

HMPerson1

@HMPerson1 · X

@hankgreen the articles that these graphs are from, for reference: https://t.co/IYDA1Vl2U9 https://t.co/7tCNxdabSR

Mar 17, 2024 · 1 like · 99 followers View post →

Juanmarcosgg

@juanmarcosgg · X

RT @RevEspCardiol: Once weekly semaglutide and cardiovascular outcomes in patients with type 2 diabetes and heart failure with reduced left…

Feb 6, 2024 · 1 share · 510 followers View post →

REC Publications

@RevEspCardiol · X

Once weekly semaglutide and cardiovascular outcomes in patients with type 2 diabetes and heart failure with reduced left ventricular ejection fraction #REC #AOP @belmonte_dr @InfoUMA @_ibima @HRegionalMalaga @CIBER_CV @RGomezHuelgas @MRBernalLopez https://t.co/5CPksDZu7y

Feb 6, 2024 · 3 likes · 1 share · 22,875 followers View post →

Nicholas Kaknes

@NickKaknes · X

@zfawx0 @QuisitiveInvest https://t.co/Lj7ekVtKyb

Dec 23, 2023 · 1 like · 226 followers View post →

Nhio Matambo

@DrMats29 · X

SEMAGLUTIDE AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES (SUSTAIN-6 TRIAL) https://t.co/XfJZ9lq6a5

Dec 21, 2023 · 166 followers View post →

Beverly G. Tchang, MD

@BevTchangMD · X

@a_h_ghoneem (Background: #Ozempic ❤️ protection driven by nonfatal stroke, https://t.co/JBa1526kWi whereas liraglutide's was driven by fatal MI, https://t.co/1IWK2n9HHX ) 6/ https://t.co/XDOlj5m20y

Dec 3, 2023 · 1 like · 6,104 followers View post →

Dr.U@糖尿病メモ

@dr_ukio · X

SUSTAIN-6でセマグルチド群で網膜症増加したことを受けてのメタ解析。 https://t.co/aSTsMP9lwv https://t.co/1ZgBrfdrCN https://t.co/G13jDz2Dav

Dec 1, 2023 · 1 like · 7,279 followers View post →

Professor M Z Khalil

@mzkhalil · X

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DM | NEJM The rate of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke was significantly lower among patients receiving #semaglutide https://t.co/z9ikways5K https://t.co/fZDuM3kWqh

Nov 15, 2023 · 1 like · 2,856 followers View post →

M Azfar Qureshi

@MAQ_Renal · X

RT @kidney_boy: Here are the adverse events from SUSTAIN-6. Balanced SAEs and no signal for pancreatitis. https://t.co/4lX3PyIqO5 https://…

Oct 12, 2023 · 3 shares · 165 followers View post →

Dr Anastasia Mihailidou FAHA FCSANZ FESC

@AnastasiaSMihai · X

RT @kidney_boy: Here are the adverse events from SUSTAIN-6. Balanced SAEs and no signal for pancreatitis. https://t.co/4lX3PyIqO5 https://…

Oct 12, 2023 · 3 shares · 19,271 followers View post →

Joel Topf

@kidneyboy.bsky.social · Bluesky

Here are the adverse events from SUSTAIN-6. Balanced SAEs and no signal for pancreatitis. https://www.nejm.org/doi/10.1056/NEJMoa1607141

Oct 12, 2023 · 1 share View post →

Joel M. Topf, MD FACP

@kidney_boy · X

Here are the adverse events from SUSTAIN-6. Balanced SAEs and no signal for pancreatitis. https://t.co/4lX3PyIqO5 https://t.co/wUFB2GziHR

Oct 12, 2023 · 9 likes · 3 shares · 63,222 followers View post →

Masato Nakazawa, Confidence Rebuilder

@arafif_hubbie · X

This randomized, double-blind, placebo controlled study was published in New England Journal of Medicine in 2016. 3/3 original article: https://t.co/v0bev3g5Yn

Sep 21, 2023 · 60 followers View post →

Theophan the Recluse Fan

@LowStudies · X

@DanielJDrucker @CaloriesProper @jerryteixeira @sguyenet @gerdosi @garytaubes @DrEades @davidludwigmd The long form of the study. https://t.co/2Ur41odcp4

Sep 7, 2023 · 5,058 followers View post →

Mind Your Science!

@MindYourSci · X

RT @sguyenet: Novo Nordisk reports that semaglutide 2.4 mg reduced cardiovascular events by 20% in ppl with obesity in the SELECT trial. C…

Aug 22, 2023 · 16 shares · 133 followers View post →

Un-nudgeable

@KPlorable · X

@KaladinFree Ozempic is good for the heart. Maybe trump should be considering. https://t.co/P9rSgxo3nA

Aug 21, 2023 · 3 likes · 4,291 followers View post →

Zaher Toumi MD

@ZaherToumi · X

RT @DrKarlNadolsky: @ZaherToumi C/w the trials! https://t.co/2VbOrrthMQ https://t.co/caxaVY7wny

Aug 20, 2023 · 1 share · 7,827 followers View post →

Karl Nadolsky

@DrKarlNadolsky · X

@ZaherToumi C/w the trials! https://t.co/2VbOrrthMQ https://t.co/caxaVY7wny

Aug 20, 2023 · 1 like · 1 share · 5,846 followers View post →

Karl Nadolsky

@DrKarlNadolsky · X

@MichaelAlbertMD @DrNadolsky From cvot & meta-analyses this is pretty consistent https://t.co/caxaVY7wny https://t.co/2VbOrrthMQ

Aug 20, 2023 · 1 like · 5,846 followers View post →

ガラパゴス伊藤@総合診療医

@galapagos_ito · X

セマグルチドのエビデンス調べてるんですが、ちょっとよくわかんなくて困ってます。セマグルチドが0.5mgでも1mgでもどっちでもいいのか知りたいんですが、本文中は0.5mg+1mgではPrimary outcomesは有意差あるけど、Appendixでは0.5mgも1mgも有意差ないんですがなぜですか？ https://t.co/u1XzHtoWik https://t.co/w1j8E52flf

Aug 17, 2023 · 2 likes · 2,402 followers View post →

Dr.Lama Amer, MD

@Dr_Lama_Amer · X

In a recent meta-analysis there was a 17% reduction in fatal and non-fatal stroke #Semaglutide leads the pack with 35% reduced stroke risk in the SUSTAIN-6 trial مراجع الدراسات: https://t.co/7zFn1W6jCz https://t.co/18vqYp03EK https://t.co/B6a04XEJBc

Aug 13, 2023 · 4,288 followers View post →

Dr Gail Ashford

@drgail3 · X

RT @sguyenet: Novo Nordisk reports that semaglutide 2.4 mg reduced cardiovascular events by 20% in ppl with obesity in the SELECT trial. C…

Aug 10, 2023 · 16 shares · 2,032 followers View post →

Kaushal Kashyap Ⓥ

@ktimesk · X

RT @sguyenet: Novo Nordisk reports that semaglutide 2.4 mg reduced cardiovascular events by 20% in ppl with obesity in the SELECT trial. C…

Aug 9, 2023 · 16 shares · 178 followers View post →

Uku Vainik

@ukuv · X

RT @sguyenet: Novo Nordisk reports that semaglutide 2.4 mg reduced cardiovascular events by 20% in ppl with obesity in the SELECT trial. C…

Aug 9, 2023 · 16 shares · 1,131 followers View post →

Jose C Souto, MD

@jcsouto · X

RT @sguyenet: Novo Nordisk reports that semaglutide 2.4 mg reduced cardiovascular events by 20% in ppl with obesity in the SELECT trial. C…

Aug 9, 2023 · 16 shares · 14,607 followers View post →

Aljosa Kuzmanovski

@Aljoo5 · X

RT @sguyenet: Novo Nordisk reports that semaglutide 2.4 mg reduced cardiovascular events by 20% in ppl with obesity in the SELECT trial. C…

Aug 9, 2023 · 16 shares · 108 followers View post →

Hugo Viegas

@HugoViegas_17 · X

RT @sguyenet: Novo Nordisk reports that semaglutide 2.4 mg reduced cardiovascular events by 20% in ppl with obesity in the SELECT trial. C…

Aug 9, 2023 · 16 shares · 19 followers View post →

Thomas Pinnock

@Thomas_Pinnock_ · X

RT @sguyenet: Novo Nordisk reports that semaglutide 2.4 mg reduced cardiovascular events by 20% in ppl with obesity in the SELECT trial. C…

Aug 9, 2023 · 16 shares · 186 followers View post →

Mary Lewis

@mem_lewis · X

RT @sguyenet: Novo Nordisk reports that semaglutide 2.4 mg reduced cardiovascular events by 20% in ppl with obesity in the SELECT trial. C…

Aug 8, 2023 · 16 shares · 1,426 followers View post →

Christian Tams MS RD LDN

@ChristianTams · X

RT @sguyenet: Novo Nordisk reports that semaglutide 2.4 mg reduced cardiovascular events by 20% in ppl with obesity in the SELECT trial. C…

Aug 8, 2023 · 16 shares · 1,258 followers View post →

Chase Campbell

@ChaseCa33292073 · X

RT @sguyenet: Novo Nordisk reports that semaglutide 2.4 mg reduced cardiovascular events by 20% in ppl with obesity in the SELECT trial. C…

Aug 8, 2023 · 16 shares · 85 followers View post →

Brock Golfs

@BrockGolfs · X

RT @sguyenet: Novo Nordisk reports that semaglutide 2.4 mg reduced cardiovascular events by 20% in ppl with obesity in the SELECT trial. C…

Aug 8, 2023 · 16 shares · 125 followers View post →

Aaron Lepeska

@AaronLepeska · X

RT @sguyenet: Novo Nordisk reports that semaglutide 2.4 mg reduced cardiovascular events by 20% in ppl with obesity in the SELECT trial. C…

Aug 8, 2023 · 16 shares · 178 followers View post →

Pere Joan Sala

@Fradbius · X

RT @sguyenet: Novo Nordisk reports that semaglutide 2.4 mg reduced cardiovascular events by 20% in ppl with obesity in the SELECT trial. C…

Aug 8, 2023 · 16 shares · 249 followers View post →

Kurt Harris MD

@radfugee · X

RT @sguyenet: Novo Nordisk reports that semaglutide 2.4 mg reduced cardiovascular events by 20% in ppl with obesity in the SELECT trial. C…

Aug 8, 2023 · 16 shares · 1,754 followers View post →

Stephan J. Guyenet

@sguyenet · X

Aug 8, 2023 · 49 likes · 16 shares · 48,848 followers View post →

Ethan J. Weiss

@ethanjweiss · X

Should have included reference to both Sustain-6 https://t.co/Ims4Mg8ukC and LEADER: https://t.co/7TgR0eLuLu

Aug 8, 2023 · 3 likes · 30,106 followers View post →

Ethan J. Weiss

@ethanjweiss · X

@matthewherper It is really that surprising based on these results? https://t.co/7TgR0eLuLu https://t.co/Ims4Mg8ukC

Aug 8, 2023 · 3 likes · 30,106 followers View post →

Nutty Buddy

@NuttyBuddy9 · X

RT @CMichaelGibson: These data in non-diabetics, builds upon previously published data in diabetics showing a 26% reduction in cardiovascul…

Aug 8, 2023 · 1 share · 229 followers View post →

Carl-Magnus Hake

@CM_Hake · X

... typ 2-diabetes som är en rejäl riskfaktor, om än att de var större (96,7 kg i snittingångsvikt mot 92,1 kg i Sustain-6) och fick en högre dos semaglutid. Läs mer om Sustain-6 här: https://t.co/iXXzc721dX

Aug 8, 2023 · 980 followers View post →

Rumpel Style

@Rumpel · X

@ThierryBorgeat Die Daten sind wissenschaftlich nix neues. Die relative Risikoreduktion für vaskuläre Ereignisse unter Semaglutid liegt bei 20-30%. Der Effekt ist nicht dosisabhängig (schon 2016: https://t.co/zkc95epc7o). Neue Indikation führt aber zu neuem Patentschutz im jeweiligen Bereich.

Aug 8, 2023 · 138 followers View post →

C. Michael Gibson MD

@CMichaelGibson · X

These data in non-diabetics, builds upon previously published data in diabetics showing a 26% reduction in cardiovascular outcomes https://t.co/WIQ8vsok1B https://t.co/CmjwKWh8O8

Aug 8, 2023 · 4 likes · 1 share · 432,202 followers View post →

Stephan J. Guyenet

@sguyenet · X

@DrRyanPDaly @MichaelAlbertMD There's already evidence that semaglutide reduces cardiovascular events comparably to statins in people with T2DM. https://t.co/oTQfAhNe79 https://t.co/dLsjoqY7Ns

Aug 2, 2023 · 8 likes · 48,848 followers View post →

Alice

@AliceFromQueens · X

@b01dface https://t.co/elfdtzn88p

Jun 28, 2023 · 46,563 followers View post →

BiotechObserver

@BiotechObserver · X

@guy84179559 @Citrini7 @KlendathuCap It would seem not. https://t.co/IPxACNu8Jd

Jun 26, 2023 · 2,794 followers View post →

@sssaoirseee · X

RT @raphaels7: * CORRECTION 6-20 bpm⬆️is for dual agonists, not semgalutide 1mg semaglutide⬆️heart rate 2.47 bpm above that of the placeb…

May 27, 2023 · 6 shares · 474 followers View post →

DrV

@DrVasquezHealth · X

RT @raphaels7: * CORRECTION 6-20 bpm⬆️is for dual agonists, not semgalutide 1mg semaglutide⬆️heart rate 2.47 bpm above that of the placeb…

May 27, 2023 · 6 shares · 2,097 followers View post →

JohnWashington

@JW09173474 · X

RT @raphaels7: * CORRECTION 6-20 bpm⬆️is for dual agonists, not semgalutide 1mg semaglutide⬆️heart rate 2.47 bpm above that of the placeb…

May 26, 2023 · 6 shares · 144 followers View post →

Dale, The Data Obsessed Fat Guy

@DOFGuy · X

RT @raphaels7: * CORRECTION 6-20 bpm⬆️is for dual agonists, not semgalutide 1mg semaglutide⬆️heart rate 2.47 bpm above that of the placeb…

May 26, 2023 · 6 shares · 119 followers View post →

colormesheesh

@colormesheesh · X

RT @raphaels7: * CORRECTION 6-20 bpm⬆️is for dual agonists, not semgalutide 1mg semaglutide⬆️heart rate 2.47 bpm above that of the placeb…

May 26, 2023 · 6 shares · 1,614 followers View post →

Citizen of EU

@wavetossed · X

RT @raphaels7: * CORRECTION 6-20 bpm⬆️is for dual agonists, not semgalutide 1mg semaglutide⬆️heart rate 2.47 bpm above that of the placeb…

May 26, 2023 · 6 shares · 9,494 followers View post →

Raphael Sirtoli

@raphaels7 · X

May 26, 2023 · 61 likes · 6 shares · 8,597 followers View post →

Alaa (آلاء) Alarbash

@3A3Dr · X

RT @Dr_Lama_Amer: @Abo_Yasser1993 تفضل المصادر https://t.co/LntZ4TNeoy https://t.co/RmphgdzT1M https://t.co/taxi9jL0En https://t.co/7z…

Apr 30, 2023 · 1 share · 66 followers View post →

Dr.Lama Amer, MD

@Dr_Lama_Amer · X

@Abo_Yasser1993 تفضل المصادر https://t.co/LntZ4TNeoy https://t.co/RmphgdzT1M https://t.co/taxi9jL0En https://t.co/7zFn1W6jCz https://t.co/uDzI9HjNLc

Apr 30, 2023 · 18 likes · 1 share · 4,288 followers View post →

Beverly G. Tchang, MD

@BevTchangMD · X

And we have the SUSTAIN-6 CVOT for semaglutide 1.0 (Ozempic) but not sema 2.4 (Wegovy), which showed #CVD benefit driven by a ↓ in stroke https://t.co/Ipe1CLssj1 3/

Jan 14, 2023 · 4 likes · 6,104 followers View post →

Dr. Sultan Al-Mutairi

@sultanalazizi · X

RT @drjoharji1: @TaibMoh12386758 دواء اوزمبيك في دراسة sustain 6 استطاع تقليل فرص حصول جلطات دماغية بنسبة ٣٩٪ مقارنة بالبلاسيبو https://t.c…

Sep 15, 2022 · 1 share · 295 followers View post →

د.عبدالرحمن جوهرجي

@drjoharji1 · X

@TaibMoh12386758 دواء اوزمبيك في دراسة sustain 6 استطاع تقليل فرص حصول جلطات دماغية بنسبة ٣٩٪ مقارنة بالبلاسيبو https://t.co/prt53Lkwmu + جرعة واحدة في الاسبوع + لايوجد خطورة هبوط في السكر + تحكم ممتاز في السكر

Sep 14, 2022 · 9 likes · 1 share · 86,716 followers View post →

DJD

@DJD81553730 · X

RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…

Aug 13, 2022 · 100 shares · 874 followers View post →

Max Lugavere

@maxlugavere · X

RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…

Aug 13, 2022 · 100 shares · 89,682 followers View post →

DigestivoValdecilla

@DigValdecilla · X

RT @JhannaCueto: Se han publicados diferentes estudios mostrando la seguridad cardiovascular y prevención de eventos en población de riesgo…

Aug 7, 2022 · 3 shares · 1,392 followers View post →

Jeffry Beltre E.

@Mr_Jeffry · X

RT @JhannaCueto: Se han publicados diferentes estudios mostrando la seguridad cardiovascular y prevención de eventos en población de riesgo…

Aug 6, 2022 · 3 shares · 2,048 followers View post →

July

@JulySeEs · X

RT @JhannaCueto: Se han publicados diferentes estudios mostrando la seguridad cardiovascular y prevención de eventos en población de riesgo…

Aug 6, 2022 · 3 shares · 17,537 followers View post →

Dra. Jhanna Cueto

@JhannaCueto · X

Se han publicados diferentes estudios mostrando la seguridad cardiovascular y prevención de eventos en población de riesgo

Aug 6, 2022 · 1 like · 3 shares · 925 followers View post →

Sintayehu Abebe

@sinta_gf · X

RT @drscottyk: Another reason to prescribe GLP1’s: Sustain6 CV trial showed semaglutide (0.5 or 1 mg) reduced CV death, MI or stroke vs pl…

Jul 21, 2022 · 5 shares · 451 followers View post →

Dr. Shashank Joshi

@AskDrShashank · X

RT @drscottyk: Another reason to prescribe GLP1’s: Sustain6 CV trial showed semaglutide (0.5 or 1 mg) reduced CV death, MI or stroke vs pl…

Jul 20, 2022 · 5 shares · 32,535 followers View post →

Michael Buratovich

@MichaelBuratovi · X

RT @drscottyk: Another reason to prescribe GLP1’s: Sustain6 CV trial showed semaglutide (0.5 or 1 mg) reduced CV death, MI or stroke vs pl…

Jul 20, 2022 · 5 shares · 1,162 followers View post →

tawfiq r choudhury

@drtrc99 · X

RT @drscottyk: Another reason to prescribe GLP1’s: Sustain6 CV trial showed semaglutide (0.5 or 1 mg) reduced CV death, MI or stroke vs pl…

Jul 20, 2022 · 5 shares · 2,403 followers View post →

Dr Scott W Murray

@DrScottMurray · X

RT @drscottyk: Another reason to prescribe GLP1’s: Sustain6 CV trial showed semaglutide (0.5 or 1 mg) reduced CV death, MI or stroke vs pl…

Jul 20, 2022 · 5 shares · 6,165 followers View post →

Scotty Kirkpatrick M.D.

@drscottyk · X

Another reason to prescribe GLP1’s: Sustain6 CV trial showed semaglutide (0.5 or 1 mg) reduced CV death, MI or stroke vs placebo (2.3% ARR, RR 26%, NNT 43) at 2 years in high risk patients with diabetes. https://t.co/mJH0ILTKh1

Jul 20, 2022 · 16 likes · 5 shares · 2,793 followers View post →

William Montaña

@WilliamMontaa10 · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Jun 28, 2022 · 49 shares · 13 followers View post →

Nikola Crncevic

@NikolaCrni179 · X

RT @drscottyk: GLP1’s are incredible! The Sustain 6CV trial showed semaglutide (0.5 or 1 mg)⬇️CV death, MI or stroke vs placebo (2.3% ARR,…

Jun 23, 2022 · 5 shares · 135 followers View post →

Raul Villar

@DrRaulvillar · X

RT @drscottyk: GLP1’s are incredible! The Sustain 6CV trial showed semaglutide (0.5 or 1 mg)⬇️CV death, MI or stroke vs placebo (2.3% ARR,…

Jun 22, 2022 · 5 shares · 409 followers View post →

Akiva Rosenzveig

@AkivaRosenzveig · X

RT @drscottyk: GLP1’s are incredible! The Sustain 6CV trial showed semaglutide (0.5 or 1 mg)⬇️CV death, MI or stroke vs placebo (2.3% ARR,…

Jun 22, 2022 · 5 shares · 1,582 followers View post →

Costas Tsakirides

@tsakirides · X

RT @drscottyk: GLP1’s are incredible! The Sustain 6CV trial showed semaglutide (0.5 or 1 mg)⬇️CV death, MI or stroke vs placebo (2.3% ARR,…

Jun 22, 2022 · 5 shares · 1,471 followers View post →

Scotty Kirkpatrick M.D.

@drscottyk · X

GLP1’s are incredible! The Sustain 6CV trial showed semaglutide (0.5 or 1 mg)⬇️CV death, MI or stroke vs placebo (2.3% ARR, RR 26%, NNT 43) at 2yrs in ⬆️risk patients with DM. Looking forward to SELECT trial results (sema 2.4 mg CV outcome trial in⬆️BMI) https://t.co/mJH0ILTKh1

Jun 22, 2022 · 14 likes · 5 shares · 2,793 followers View post →

cardio-met

@cardiomet_CE · X

24c)

May 11, 2022 · 2 likes · 4,157 followers View post →

The Cardiometabolic Forum

@theCMforum · X

Husain M et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. @NEJM 2019. View the summary here: https://t.co/JCHWGlF9IM

Feb 17, 2022 · 257 followers View post →

Endocrine dialogues

@EndoDialogues · X

It is still 2016 Less than 4 months after LEADER, SUSTAIN-6 comes. Semaglutide, another GLP-1 receptor agonist, shows to ⬇️ the composite outcome of stroke/myocardial infarction/cardiovascular death pts with T2D and⬆️ CV risk! SUSTAIN-6 https://t.co/J1YrLm0tb7 (8/13)

Jan 15, 2022 · 14 likes · 6,483 followers View post →

David Macklin

@DavidMacklinMD · X

@MichaelAlbertMD

Jan 2, 2022 · 1 like · 1,861 followers View post →

syed shaban

@SydShaban · X

RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…

Dec 2, 2021 · 100 shares · 251 followers View post →

أ.د. وليد البكر

@DrWaleedalbaker · X

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes | NEJM https://t.co/lXeazVTECi

Oct 2, 2021 · 1 like · 45,716 followers View post →

Endocrine dialogues

@EndoDialogues · X

In many other studies, drugs proved to have the same impressive and unexpected benefits. https://t.co/TqtU2tjpJX https://t.co/Ff9utEIhxR

Mar 20, 2021 · 2 likes · 6,483 followers View post →

Scott Morgans

@Scott_Morgans1 · X

Lots of people especially in the fitness industry up in arms, that medication isn’t the answer etc... However, semaglutide is showing real positive benefits around appetite suppression and its effects as a whole on CVD risk. https://t.co/iogIEvsHCS

Feb 20, 2021 · 268 followers View post →

Kausik

@kausikdatta22 · X

With me so far? Proper management of blood sugar—coupled with hunger suppression—is likely responsible for Semaglutide’s lowering of metabolic & heart risk factors (eg, blood pressure, HbA1c, cholesterol, triglycerides) + *secondary* weight loss effect. 7️⃣ https://t.co/DniDqLAFEy

Feb 18, 2021 · 1,723 followers View post →

Josh Beckman

@JoshuaBeckmanMD · X

@Plasmacellguy @Ultracardiodoc @skathire Well this is a good Rex for diabetes that reduces CV events, so I’m not sure what you are worried about. https://t.co/eWnxUG5vYr

Feb 11, 2021 · 2 likes · 2,158 followers View post →

Dr. Spencer Nadolsky

@DrNadolsky · X

@KCKlatt @Hogwood_AC @ProfBatterhamMD @BrownAdey @KevinH_PhD @BioLayne Lower dose but CVD event benefit https://t.co/biZMQfFHrR

Feb 10, 2021 · 6 likes · 58,873 followers View post →

benito Camela

@carlosedu1819 · X

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes Facebook:https://t.co/HMxlBrjB97 Youtube :https://t.co/SyUqiPCRv8

Feb 9, 2021 · 6 likes · 145 followers View post →

Juan Senior

@jsenior64 · X

https://t.co/AhWtOdVpnY

Jan 11, 2021 · 11,064 followers View post →

Physician's Weekly

@physicianswkly · X

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/GSD9U1Z0uq

Aug 18, 2020 · 6,344 followers View post →

Annyka

@Annyka73458918 · X

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes , LINK VIDEO: https://t.co/1O9ekwufqw

Jul 28, 2020 View post →

Mohammed

@_7M0DY_ · X

https://t.co/YkPGSAzrF1

Jul 27, 2020 · 1,162 followers View post →

おだQ

@OdaQ_DM · X

GLP-1受容体作動薬の心血管エビデンス一覧2 ・リキセナチド（商品名リキスミア) ELIXA https://t.co/xuafQgvrFE ・セマグルチド(商品名オゼンピック) SUSTAIN 6 https://t.co/GbRauHohsf PIONEER 6(経口) https://t.co/DcznGmE55E ・アルビグルチド(日本非発売) HARMONY OUTCOMES

Jun 16, 2020 · 15 likes · 1 share · 15,213 followers View post →

Stephan J. Guyenet

@sguyenet · X

@FrogHarmless Always possible. But to date, the most notable health-related side effect is a substantial reduction in cardiovascular event risk in people with T2DM. https://t.co/bJgJqI9ABh

May 14, 2020 · 1 like · 48,848 followers View post →

Fernand Bteich, MD, MS

@fernandbteich · X

9/ Weight loss was also prominent with semaglutide (as high as 6kg or 13lbs). Maximal effect on glycemia is reached ~10-16wks after starting treatment. Weight loss plateau is reached after ~10wks. N Engl J Med 2016; 375:1834-1844 DOI:10.1056/NEJMoa1607141 ⬇️ https://t.co/N66BMBNlJA

Apr 30, 2020 · 3 likes · 1,910 followers View post →

GrupoCronosSEFH

@GRUPOCRONOSSEF1 · X

Para hoy jueves refrescamos este artículo del mes pasado de @NEJM Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes Disponible en: https://t.co/g3CYDkWxeb

Nov 7, 2019 · 1 like · 3,323 followers View post →

名前

@akkiii0830 · X

SUSTAIN6 CVOT https://t.co/HmqdU9w1ir

Sep 30, 2019 · 1 like · 248 followers View post →

Omid Hakami Hakami

@Omidhakami · X

RT @FarmaMadridAP: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes via @NEJM https://t.co/mjG7ikfb7r

Sep 25, 2019 · 3 shares · 505 followers View post →

Salvador Rivera

@salvarivera · X

RT @FarmaMadridAP: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes via @NEJM https://t.co/mjG7ikfb7r

Sep 25, 2019 · 3 shares · 220 followers View post →

Marcelo Mario Avellanal Leal

@parreshia · X

RT @FarmaMadridAP: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes via @NEJM https://t.co/mjG7ikfb7r

Sep 25, 2019 · 3 shares · 2,010 followers View post →

Farmacia Madrid AP

@FarmaMadridAP · X

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes via @NEJM https://t.co/mjG7ikfb7r

Sep 25, 2019 · 2 likes · 3 shares · 8,348 followers View post →

KristopherMaday PA-C

@PA_Maday · X

PIONEER 6 Trial Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/jLHVJMtbYb https://t.co/Zf65V5o7o8

Sep 23, 2019 · 2,461 followers View post →

Diego Peñailillo Güenante

@nachX · X

@JuanPeirano Los GLP1-RA tienen efecto demostrado de la disminución de MACE https://t.co/lNPaeOF8iT https://t.co/Mt9yLDpQlX

Sep 19, 2019 · 759 followers View post →

Anand. A Hardikar

@AnandHardikar · X

RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…

Sep 11, 2019 · 100 shares · 840 followers View post →

rodrigo zumbado

@zumbadoMD · X

RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…

Sep 10, 2019 · 100 shares · 201 followers View post →

Dr. Gilberto Pérez López MD PhD

@Endocrino_PED · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 7, 2019 · 49 shares · 4,774 followers View post →

Umar Shakur

@u_shakur · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 6, 2019 · 49 shares · 292 followers View post →

Teja naveen

@tejanaveenbolem · X

RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…

Sep 5, 2019 · 100 shares · 101 followers View post →

散歩ミカン

@sanpo_mikan · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 4, 2019 · 49 shares · 338 followers View post →

散歩ミカン

@sanpo_mikan · X

2型糖尿病患者における経口セマグルチドと心血管転帰 Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. M. Husain and Others. N Engl J Med 2019; 381:841-851. https://t.co/B8EiDYWyTd

Sep 4, 2019 · 2 likes · 338 followers View post →

RODRIGO LUNA

@RODRIGO32984659 · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 4, 2019 · 49 shares · 20 followers View post →

orlando henne

@ohenne2 · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 4, 2019 · 49 shares · 253 followers View post →

leo uzych

@LeoUzych · X

Oral #Semaglutide and #Cardiovascular Outcomes in Patients with Type 2 #Diabetes | #NEJM https://t.co/5EyJmwKrxu

Sep 4, 2019 · 223 followers View post →

Dr.Marco Antonio C

@drmarcocamacho · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 4, 2019 · 49 shares · 1,154 followers View post →

María Antequera

@mellitus_1 · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 4, 2019 · 49 shares · 1,608 followers View post →

SaludHEALTHinfo

@SaludHEALTHinfo · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 4, 2019 · 49 shares · 8,865 followers View post →

María Ballesteros

@mdballesteros · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 4, 2019 · 49 shares · 4,775 followers View post →

Akif Acay

@akifacay · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 3, 2019 · 49 shares · 247 followers View post →

Leslie David, MD

@Sportslad · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 3, 2019 · 49 shares · 184 followers View post →

PublicHealthMaps

@PublicHealthMap · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 3, 2019 · 49 shares · 6,352 followers View post →

Marina

@Marina_nefro · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 3, 2019 · 49 shares · 935 followers View post →

Ana Piera #JuntosEsMasFacil

@ana_apiecar · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 3, 2019 · 49 shares · 2,573 followers View post →

Iván

@Dockat16 · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 3, 2019 · 49 shares · 88 followers View post →

Stefania Arciello

@StefaniaArciell · X

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes | NEJM https://t.co/bQuSFrPUy0

Sep 3, 2019 · 1,947 followers View post →

ligiamendes

@ligiamendes76 · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 3, 2019 · 49 shares · 30 followers View post →

Manuel Beltrán

@ManoloBeltranR · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 3, 2019 · 49 shares · 578 followers View post →

Carlos

@cavicae22 · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 3, 2019 · 49 shares · 77 followers View post →

Cristobal Morales

@CristobMorales · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 3, 2019 · 49 shares · 17,028 followers View post →

Manuel Ruelas

@ManuelRuelas21 · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 3, 2019 · 49 shares · 423 followers View post →

Tu Endocrino

@TuendocrinoSEEN · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 3, 2019 · 49 shares · 5,765 followers View post →

( ノ´.ㅅ` )ノรางวัลที่ 1 มาแน่!!!

@lexokkaz2 · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 3, 2019 · 49 shares · 79 followers View post →

J. Cena

@DrJCena · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 3, 2019 · 49 shares · 166 followers View post →

Medical Research Library of Brooklyn

@DMCLibraryBKLYN · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 3, 2019 · 49 shares · 327 followers View post →

Hanna Gaggin

@HannaGaggin · X

RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…

Sep 3, 2019 · 100 shares · 1,611 followers View post →

Smileyploi:D

@Jpolyploid1 · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 3, 2019 · 49 shares · 6 followers View post →

Dr.Yasser Alwali

@DrYasserAlwali · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 3, 2019 · 49 shares · 445 followers View post →

Unya S

@UnyaS · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 3, 2019 · 49 shares · 187 followers View post →

Yevgen Zolotarov

@zolotarov · X

RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…

Sep 3, 2019 · 100 shares · 49 followers View post →

Dr. Perez-Belmonte

@belmonte_dr · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 3, 2019 · 49 shares · 150 followers View post →

FAM

@alvmufa · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 3, 2019 · 49 shares · 383 followers View post →

Rafael Aguilella

@rafaelaguilella · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 3, 2019 · 49 shares · 149 followers View post →

Dr. Karoki

@Dr_karoki · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 3, 2019 · 49 shares · 190 followers View post →

APL

@AndreaPestanaL · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 3, 2019 · 49 shares · 1,774 followers View post →

Jose Ferreira Santos

@japfs · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 3, 2019 · 49 shares · 237 followers View post →

平社員

@T462759 · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 3, 2019 · 49 shares · 274 followers View post →

Don Epezilo

@seinanathema · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 3, 2019 · 49 shares · 450 followers View post →

horottoilvetro

@horottoilvetro · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 3, 2019 · 49 shares · 3,110 followers View post →

M Shafi Kuchay

@drshafikuchay · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 3, 2019 · 49 shares · 19,840 followers View post →

Pharmacy Updates

@NaplexReviewQs · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 3, 2019 · 49 shares · 375 followers View post →

Dr Jean Pierre Laroche #vacciné 6.0

@Echoraljpangio · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 3, 2019 · 49 shares · 2,714 followers View post →

Mafer

@Mafer_XHP · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 3, 2019 · 49 shares · 628 followers View post →

Pub Health Monitor

@monitor_PH · X

RT @NEJM: #VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.…

Sep 3, 2019 · 49 shares · 1,823 followers View post →

NEJM

@NEJM · X

#VisualAbstract: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://t.co/FuAPUe1QVJ https://t.co/vfSvtmms4a

Sep 3, 2019 · 76 likes · 49 shares · 935,501 followers View post →

Michael Buratovich

@MichaelBuratovi · X

RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…

Sep 2, 2019 · 100 shares · 1,162 followers View post →

Mehroz Ehsan

@mehrozehsan · X

RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…

Sep 2, 2019 · 100 shares · 454 followers View post →

François Marchildon

@FMarchildon · X

RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…

Sep 2, 2019 · 100 shares · 154 followers View post →

Vladimir Heiskanen

@ValtsuH · X

RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…

Sep 2, 2019 · 100 shares · 797 followers View post →

Santito

@SantitoBastardo · X

RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…

Sep 2, 2019 · 100 shares · 66 followers View post →

Stephen Heitner

@HeitnerStephen · X

RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…

Sep 2, 2019 · 100 shares · 600 followers View post →

Dylan

@sp6c3inv6d3r · X

RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…

Sep 2, 2019 · 100 shares · 330 followers View post →

Paul Knoepfler

@pknoepfler · X

RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…

Sep 2, 2019 · 100 shares · 20,568 followers View post →

Jan Vyjidak

@janvyjidak · X

RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…

Sep 2, 2019 · 100 shares · 4,152 followers View post →

Biotech-Catalyst

@BIOTECH888 · X

RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…

Sep 1, 2019 · 100 shares · 214 followers View post →

Zahraddin Abdullahi

@Xahraddin_A · X

RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…

Sep 1, 2019 · 100 shares · 1,372 followers View post →

Matthew Theisen

@RealTheisen · X

RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…

Sep 1, 2019 · 100 shares · 32 followers View post →

Yanfei Zhang

@zhyanfei123 · X

RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…

Sep 1, 2019 · 100 shares · 59 followers View post →

Abhishek Kulkarni

@AbhiKulk82 · X

RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…

Sep 1, 2019 · 100 shares · 524 followers View post →

JUSTADUDE

@mookiemanboi · X

RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…

Sep 1, 2019 · 100 shares · 900 followers View post →

Jan Ehses

@JanEhses · X

RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…

Sep 1, 2019 · 100 shares · 1,729 followers View post →

Tune H. Pers

@tunepers · X

RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…

Sep 1, 2019 · 100 shares · 1,376 followers View post →

Raymond Francis Sarmiento, M.D.

@rfrsarmiento · X

RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…

Sep 1, 2019 · 100 shares · 1,551 followers View post →

George Thampy

@GeorgeThampy · X

RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…

Sep 1, 2019 · 100 shares · 889 followers View post →

George Dawson

@dawso007 · X

RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…

Sep 1, 2019 · 100 shares · 7,816 followers View post →

David Macklin

@DavidMacklinMD · X

@AnilMakam @VPrasadMDMPH Yet Anil we have many DM2 meds , but we have NO other diabetes medications that can, with behavioural support, generate a mean weight loss of 18+ percent at one year. And also with + Cardiovascular safety https://t.co/kBG0tLXkfo in non-inferiority study https://t.co/nQ9Sb4YgqL

Aug 31, 2019 · 1,861 followers View post →

Florian Wünnemann

@flowuenne · X

RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…

Aug 31, 2019 · 100 shares · 473 followers View post →

SY Investing

@syinvesting · X

RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…

Aug 31, 2019 · 100 shares · 5,240 followers View post →

subbakrishna rao

@SubkrishnaRao · X

RT @skathire: An oral drug which: 1. leads to meaningful weight loss 2. lowers all-cause mortality ~50% 3. lowers CV mortality 4. lowers hg…

Aug 31, 2019 · 100 shares · 1,330 followers View post →

Neil Floch MD

@NeilFlochMD · X

RT @RpratleyMD: Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes | NEJM https://t.co/YKHeUdNFIT #ADA2019

Jun 19, 2019 · 5 shares · 130,123 followers View post →

Ethical GmbH

@Ethicalgmbh · X

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes | NEJM https://t.co/WTmOOp1kms

Jun 17, 2019 · 488 followers View post →

Viri diana

@viridiana_dlt · X

RT @RpratleyMD: Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes | NEJM https://t.co/YKHeUdNFIT #ADA2019

Jun 12, 2019 · 5 shares · 101 followers View post →

Basem Mishriky, MD, FACP, ABOM Diplomate

@BasemMishriky · X

RT @RpratleyMD: Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes | NEJM https://t.co/YKHeUdNFIT #ADA2019

Jun 11, 2019 · 5 shares · 271 followers View post →

Dr. Fermin Gonzalez

@fermin98380786 · X

RT @RpratleyMD: Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes | NEJM https://t.co/YKHeUdNFIT #ADA2019

Jun 11, 2019 · 5 shares · 590 followers View post →

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Mentions per month

Where it's discussed

What people are saying

Abstract in brief

Top posts

All mentions